Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2024 09:52 ET | Source: Hagens Berman Sobol Shapiro LLP

EGRX FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities Fraud Class Action

SAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class Period:...
February 05, 2024 09:55 ET | Source: Hagens Berman Sobol Shapiro LLP

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class Period:...
February 01, 2024 16:05 ET | Source: Hagens Berman Sobol Shapiro LLP

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

SAN FRANCISCO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class...
January 29, 2024 13:01 ET | Source: Hagens Berman Sobol Shapiro LLP

EGRX 11-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities Fraud Class Action

SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class Period:...
January 26, 2024 09:12 ET | Source: Hagens Berman Sobol Shapiro LLP

Eagle Pharmaceuticals’ (EGRX) Line of Credit Reduced Amid Pending Restatement and Securities Fraud Class Action - Hagens Berman

SAN FRANCISCO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class Period:...
January 19, 2024 12:13 ET | Source: Hagens Berman Sobol Shapiro LLP

Eagle Pharmaceuticals’ (EGRX) Line of Credit Reduced Amid Pending Restatement and Securities Fraud Class Action - Hagens Berman

SAN FRANCISCO, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class Period:...
January 15, 2024 15:45 ET | Source: Hagens Berman Sobol Shapiro LLP

EGRX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm, Securities Fraud Lawsuit Filed After Company Admits Accounting Problems

SAN FRANCISCO, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class...
January 12, 2024 10:12 ET | Source: Hagens Berman Sobol Shapiro LLP

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

SAN FRANCISCO, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class Period:...
January 08, 2024 17:43 ET | Source: Hagens Berman Sobol Shapiro LLP

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class Period:...
January 05, 2024 14:03 ET | Source: Hagens Berman Sobol Shapiro LLP

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm, Securities Fraud Lawsuit Pending over Accounting Woes

SAN FRANCISCO, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class Period:...